Xeris Biopharma (XERS) Projected to Post Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $74.1920 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to analysts’ expectations of $64.58 million. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Trading Up 0.4%

Shares of XERS traded up $0.04 during trading hours on Tuesday, reaching $9.94. The company had a trading volume of 989,793 shares, compared to its average volume of 2,450,420. The firm has a 50 day simple moving average of $8.33 and a 200-day simple moving average of $6.27. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -47.40 and a beta of 0.21. Xeris Biopharma has a 12-month low of $2.82 and a 12-month high of $10.02.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Oppenheimer increased their price target on shares of Xeris Biopharma from $8.00 to $18.00 and gave the company an “outperform” rating in a report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 18th. HC Wainwright began coverage on shares of Xeris Biopharma in a research note on Tuesday, August 12th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Leerink Partners increased their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, August 19th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.92.

Insider Activity

In related news, Director John Johnson sold 107,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total value of $786,900.00. Following the sale, the director directly owned 833,483 shares of the company’s stock, valued at approximately $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Marla Persky sold 15,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the sale, the director directly owned 142,000 shares in the company, valued at $1,096,240. This represents a 9.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 207,732 shares of company stock valued at $1,550,437 over the last quarter. 4.56% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of XERS. Royal Bank of Canada raised its holdings in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after buying an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares during the period. Millennium Management LLC raised its stake in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP purchased a new stake in shares of Xeris Biopharma during the first quarter valued at approximately $170,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.